From CNBC: 2024-09-08 08:00:01

Leqembi, an Alzheimer’s drug from Biogen and Eisai, is not a cure but helps patients like Missie Meeks live more independently since receiving approval in July 2023. Although the treatment slows memory decline for patients in early stages of Alzheimer’s, it comes with risks. The drug’s rollout has been hindered by diagnosis delays and insurance challenges.

For patients like Tracey Collins, receiving a diagnosis of early Alzheimer’s can take years due to factors such as age, other health issues, and physician availability. Finding a neurologist is also a challenge, with limited availability in the U.S. beyond urban areas. Even after diagnosis, patients face hurdles determining eligibility for Leqembi due to tests and insurance coverage.

Patients seeking treatment with Leqembi must undergo PET scans or spinal fluid tests to determine the presence of amyloid in the brain and rule out other conditions. Genetic testing for a specific gene variant may also be required. A panel of experts assesses patient eligibility for the treatment. Despite the hurdles, more patients appear to be taking Leqembi, with sales increasing significantly in 2023.

The complex process of diagnosing, determining eligibility, and obtaining insurance coverage for Leqembi poses challenges for patients and healthcare providers. Despite the risks and difficulties associated with the treatment, some patients and their families believe the benefits of slowing Alzheimer’s progression outweigh the challenges. The drug is seen as a breakthrough in Alzheimer’s treatment, opening up new possibilities for patients in the early stages of the disease.



Read more at CNBC: Leqembi could give Alzheimer’s patients more time, but road to treatment is long